Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8303199 | 0.97 | HTR1A (0.43) | HTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL8303869 | 0.93 | ALDH1A1 (0.40) | HTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL8306494 | 0.86 | ALDH1A1 (0.52) | HTR1ADRD2ALDH1A1 | |
| SCHEMBL8303443 | 0.83 | HTR1A (0.58) | HTR1ADRD2 | |
| SCHEMBL8303559 | 0.80 | HTR1A (0.74) | HTR1ADRD2 | |
| SCHEMBL8302093 | 0.80 | ALDH1A1 (0.39) | HTR1ADRD2ALDH1A1 | |
| SCHEMBL8304635 | 0.78 | DRD4 (0.43) | HTR1ADRD2ALDH1A1 | |
| SCHEMBL8303204 | 0.77 | HTR1A (0.69) | HTR1ADRD2 | |
| SCHEMBL9175463 | 0.74 | DRD2 (0.42) | HTR1ADRD2HTR2A | |
| SCHEMBL8307032 | 0.73 | HRH3 (0.50) | HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0574313-B1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR (FR) | 1999-10-06 | — | — | EP | disclosed |
| US-5464834-A | Antidepressants, central nervous system | ADIR ET COMPAGNIE (FR) | 1995-11-07 | — | — | US | disclosed |
| EP-0574313-A1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-12-15 | — | — | EP | disclosed |